The SGLT2 inhibitors market is forecast to expand from USD 19 billion in 2026 to USD 34.6 billion by 2036, registering a 6.2% CAGR over the forecast period. Fact.MR attributes this expansion to the increasing prevalence of type 2 diabetes, growing demand for effective blood glucose management, and wider use of SGLT2 inhibitors in treating heart failure and chronic kidney disease. The market was valued at USD 17.9 billion in 2025 and is expected to generate an absolute dollar opportunity of USD 15.6 billion between 2026 and 2036.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors help lower blood glucose by increasing glucose excretion through the kidneys. Their clinical applications are expanding beyond diabetes management as evidence supports cardiovascular and kidney-related benefits. Updated treatment guidelines, broader regulatory approvals, and increasing awareness among healthcare professionals are supporting their integration into multiple treatment pathways. However, high medication costs and competition from other diabetes therapies remain important considerations for market participants.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=14430

Jardiance Maintains Leading Position in SGLT2 Inhibitor Treatment

By drug type, Jardiance (empagliflozin) is expected to account for 55.3% of the SGLT2 inhibitors market in 2026. Its established clinical performance in managing type 2 diabetes and reducing cardiovascular risks supports continued adoption. The drug's broader therapeutic applications, including heart failure and chronic kidney disease management, are also strengthening its position among healthcare providers.

Type 2 diabetes represents the largest indication segment, projected to capture 71.8% of market demand in 2026. The growing prevalence of diabetes, associated with obesity, aging populations, and changing lifestyles, continues to increase the need for effective treatment options. SGLT2 inhibitors are increasingly considered in treatment plans because they help manage blood glucose while offering additional cardiovascular and renal benefits.

Combination therapies are another area attracting attention. Healthcare professionals are evaluating treatment approaches that address diabetes alongside cardiovascular and kidney complications. This is creating opportunities for pharmaceutical manufacturers to expand therapeutic portfolios and develop treatment options suited to patients with multiple chronic conditions.

China, Germany, and France Show Strong Growth Potential

China is projected to register an 8.4% CAGR from 2026 to 2036, representing the highest growth rate among the countries assessed by Fact.MR. The country's large diabetic population, improving healthcare infrastructure, and increasing availability of advanced diabetes treatments are supporting market expansion. Growing awareness of cardiovascular and kidney complications associated with diabetes is also encouraging wider consideration of SGLT2 inhibitors.

Germany is expected to advance at a 7.1% CAGR during the same period. Its established healthcare infrastructure, growing diabetes prevalence, and adoption of advanced treatment options are supporting demand. The increasing use of SGLT2 inhibitors for cardiovascular protection and chronic kidney disease management is contributing to their relevance across specialist care settings.

France is forecast to grow at a 6.5% CAGR through 2036. Government support for healthcare improvements, greater attention to diabetes management, and growing interest in preventive treatment approaches are contributing to market development. Healthcare providers are increasingly considering therapies that address blood glucose control alongside associated cardiovascular and renal conditions.

India is projected to record a 7.7% CAGR, supported by its expanding diabetic population and improving healthcare awareness. The United Kingdom is expected to grow at 5.9%, reflecting established diabetes care programs and continued adoption of SGLT2 inhibitor treatments. The USA is forecast to advance at 5.3%, supported by its large diabetes patient population and access to advanced therapies, while Brazil is expected to register a 4.6% CAGR.

Competitive Landscape

Competition in the SGLT2 inhibitors market includes pharmaceutical manufacturers investing in clinical research, regulatory approvals, and expanded therapeutic indications. Key companies profiled by Fact.MR include AstraZeneca PLC, Boehringer Ingelheim International GmbH, Merck & Co., Inc., and Johnson & Johnson Services, Inc. Other participants include Eli Lilly and Company, Lexicon Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Limited, and TheracosBio, LLC.

Manufacturers are focusing on clinical differentiation, treatment effectiveness, and broader patient access. Competition is also being influenced by the development of alternative diabetes therapies and the increasing importance of demonstrating cardiovascular and renal outcomes. Companies with established treatment portfolios and clinical research capabilities remain positioned to address changing requirements across diabetes and related chronic disease management.

Clinical Research and Regulatory Developments Shape the Market

The market is entering a period of broader clinical application. Fact.MR highlights research examining the effectiveness of SGLT2 inhibitors in patients with diabetes and additional health complications. A February 2026 cohort study published in JAMA Network Open associated SGLT2 inhibitor use with lower risks of end-stage kidney disease, major adverse cardiovascular events, and hepatic decompensation among patients with type 2 diabetes and liver cirrhosis.

Research comparing different diabetes treatment classes is also influencing clinical discussions. A 2026 nationwide comparative effectiveness study from Denmark, cited in the report, found a 19% greater relative reduction in chronic kidney disease progression risk with SGLT2 inhibitor initiation compared with GLP-1 receptor agonist initiation among patients with type 2 diabetes.

Treatment guidelines and regulatory approvals remain central to future adoption. As clinical evidence develops, pharmaceutical manufacturers are expected to pursue broader indications and treatment combinations. Cost considerations, reimbursement policies, and competition from established and emerging therapies will continue to influence prescribing decisions.

Growing demand for diabetes management and expanding recognition of cardiovascular and kidney-related benefits are expected to support the SGLT2 inhibitors market through 2036. The full Fact.MR report provides detailed market forecasts, therapeutic segment analysis, country-level growth assessments, and competitive insights.

Top Reports:

https://adamaamresearch.blogspot.com/2026/10/uk-rna-therapy-clinical-trials-market.html

https://net-pals.com/blogs/53463/UK-RNA-Therapy-Clinical-Trials-Market-Expansion-Led-by-England

https://acmingle.com/blogs/30250/UK-RNA-Therapy-Clinical-Trials-Market-Forecast-to-Hit-USD

About Fact.MR

Fact.MR is a market research and consulting company providing market intelligence, competitive analysis, and forecasting across global industries. Its research supports businesses with data-driven insights into emerging markets, technology trends, competitive dynamics, regional opportunities, and changing demand patterns.